Download the free Cancer Therapy Advisor app now!
The Cancer Therapy Advisor app is a free, easy-to-use app that offers oncology professionals the latest in oncology news and emerging trends, as well as cancer treatment regimens, full-length features, slideshows, case studies, and drug information for a variety of cancer types and therapeutic areas.
Download Cancer Therapy Advisor for free and access us on the go! Register for CTA directly from your device or log in using your existing account details.
What you'll find on the Cancer Therapy Advisor app
Our popular Viewpoint features discuss the latest developments by your colleagues.
Supplemental courses of treatment for various types of cancers including dosing, administration and management of related adverse events.
Hundreds of oncology-specific accredited courses from our partners at the myCME education library. Claim your certificate instantly!
Our calculators can assess liver function, convert HbA1C to mean plasma glucose, evaluate BP, determine BMI and more, at the point-of-care.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models